Loading...
Loading...
Sector-Specific AI
Clinical accuracy. Physician speed.
Capabilities
Analyze X-rays, CT scans, MRIs, and ultrasound images for abnormalities, lesions, fractures, and disease indicators. Highlight regions of interest with confidence scores to assist radiologist review.
Provide evidence-based diagnostic suggestions based on patient symptoms, lab results, medical history, and imaging findings. Reference current clinical guidelines and relevant research for each recommendation.
Identify early indicators of cancer, cardiovascular disease, diabetic retinopathy, and neurological conditions at stages when intervention is most effective. Screen population-level data for at-risk patients.
Digitize and analyze histopathology slides for cell classification, mitotic counting, and tumor grading. Process whole-slide images at 40x magnification with sub-cellular precision.
Generate structured radiology and pathology reports from AI findings, pre-populated with measurements, comparisons to prior studies, and standardized terminology (BI-RADS, Lung-RADS, PI-RADS).
Use Cases
According to the Radiological Society of North America, radiologists read an average of one image every 3-4 seconds during a typical workday, with error rates increasing after 4 hours of continuous reading due to fatigue and volume pressure. The AI diagnostics platform pre-screens all incoming imaging studies, prioritizing critical findings and highlighting suspicious regions for radiologist review. A 2024 Lancet Digital Health meta-analysis found that AI-augmented radiology achieves 94.5% sensitivity and 92.3% specificity across multiple imaging modalities, matching or exceeding average radiologist performance while reducing reading time by 30-40%. The system detects incidental findings that radiologists might deprioritize — small pulmonary nodules, early osteoporotic changes, and hepatic lesions outside the primary area of clinical concern. Critical finding alerts ensure stroke, pulmonary embolism, and pneumothorax cases are flagged within 60 seconds of image acquisition, reaching the on-call radiologist immediately rather than waiting in the reading queue. Automated comparison with prior studies highlights interval changes, measuring growth rates and tracking treatment response across sequential examinations with precision that manual side-by-side comparison cannot match.
The International Diabetes Federation reports that 537 million adults worldwide have diabetes, with diabetic retinopathy affecting one-third of diabetic patients and being the leading cause of preventable blindness in working-age adults. Annual retinal screening is recommended but capacity-constrained — India has one ophthalmologist per 107,000 people in rural areas. A 2025 WHO Digital Health study found that AI retinal screening achieves 96.8% sensitivity for referable diabetic retinopathy, enabling deployment at primary health centers staffed by trained technicians rather than requiring specialist ophthalmologists. The AI platform analyzes retinal images captured by fundus cameras at primary care points, grading diabetic retinopathy severity and identifying macular edema, glaucoma indicators, and hypertensive retinopathy in the same examination. Patients with referable findings receive automated referral letters to specialist centers with annotated images and grading reports. Population-level screening data helps public health authorities track diabetic retinopathy prevalence, identify underscreened communities, and allocate ophthalmology resources based on disease burden rather than geographic convenience.
According to the College of American Pathologists, pathologist workload has increased 40% over the past decade while workforce growth has remained flat, creating diagnostic bottlenecks that delay cancer treatment initiation. The AI platform digitizes histopathology slides and performs automated analysis for cell classification, mitotic counting, tumor margin assessment, and standardized grading across cancer types. A 2024 Nature Medicine study found that AI pathology assistants reduce slide analysis time by 55% while improving inter-observer grading consistency from 73% to 91% agreement among reviewing pathologists. The system identifies regions of diagnostic significance in whole-slide images, allowing pathologists to focus their expertise on areas that matter rather than scanning entire slides at high magnification. Immunohistochemistry quantification automates HER2 scoring, Ki-67 counting, and PD-L1 assessment with reproducibility that exceeds manual scoring, directly impacting treatment selection for targeted and immunotherapy protocols. Quality assurance features flag slides with tissue processing artifacts, staining inconsistencies, or focus problems that could affect diagnostic accuracy, ensuring technical quality before pathologist review time is invested.
Frequently Asked Questions
No. The AI serves as a decision support tool that assists physicians — it does not replace them. All AI findings are reviewed and confirmed by qualified physicians before clinical action. The system highlights areas of concern, suggests possible diagnoses, and provides reference evidence, but the final diagnostic decision and clinical responsibility remain with the treating physician. This approach is consistent with medical device regulations worldwide.
The platform is designed to meet CDSCO (Central Drugs Standard Control Organisation) requirements for medical device software in India, FDA 510(k) requirements for the US market, and CE marking for European deployment. Specific module certifications vary by clinical application — contact our regulatory affairs team for current certification status of each diagnostic module.
Meta-analyses show the AI achieves 94.5% sensitivity and 92.3% specificity, matching average radiologist performance across multiple imaging modalities. However, the AI's primary value is not replacing radiologists but augmenting them — AI catches findings that overworked radiologists miss, and radiologists catch contextual nuances that AI misses. The combination of AI + radiologist consistently outperforms either working alone.
Yes. The platform integrates with all major PACS (Philips, GE, Siemens, Fujifilm, Agfa) and hospital information systems through DICOM and HL7 FHIR standards. Images are received directly from imaging modalities through the existing PACS workflow. AI findings are returned as DICOM Structured Reports and attached to the patient study in PACS. No changes to existing clinical workflows are required — the AI layer is transparent to end users.
The platform complies with HIPAA (US), DPDPA (India), and GDPR (EU) requirements. Patient images are encrypted in transit and at rest. On-premises deployment keeps all data within the hospital network — no patient data leaves the facility. Cloud deployment options use healthcare-certified data centers with BAA agreements. All access is logged, role-controlled, and auditable. De-identification tools remove PHI from images used for model improvement.
Tell us what you're trying to solve. We'll show you exactly how AI Healthcare Diagnostics fits your operations.